Yet another drug maker is under scrutiny for its pricing.

The US Department of Justice last Thursday sent grand jury subpoenas to Taro Pharmaceuticals and two of its senior commercial officers in its US unit seeking documents about generic pharmaceuticals and pricing, according to a filing that Taro made with the US Securities and Exchange Commission.

The filing was very brief, but noted that the feds are also looking for “communications with competitors and others” regarding the sale of generic drugs. In its filing, the company said it plans to respond and cooperate with the investigation. A Taro spokesman declined further comment.